Super Biased Ligands for Treatment of Type II Diabetes
We have very exciting results showing that we can develop compounds, “super biased ligands”, that simultaneously stimulate glucose uptake in muscle and brown fat through a novel insulin independent signalling pathway. The compounds radically reduce blood glucose levels in rodent diabetes models and our goal is to develop them to a preCD for the treatment of type 2 diabetes and forge a business alliance with a pharmaceutical company.
1 926 440.00€
Pharmaceutical Products / Drugs